AIM
CERE

Anchor Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Anchor Investment Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$4.09K – 1087
2024
Q2 		$4.09K Hold
100
– – ﹤0.01% 857
2024
Q1 		$4.23K Hold
100
– – ﹤0.01% 879
2023
Q4 		$4.24K Hold
100
– – ﹤0.01% 832
2023
Q3 		$2.18K Hold
100
– – ﹤0.01% 889
2023
Q2 		$3.18K Hold
100
– – ﹤0.01% 863
2023
Q1 		$2.44K Hold
100
– – ﹤0.01% 890
2022
Q4 		$3.15K Hold
100
– – ﹤0.01% 845
2022
Q3 		$2.83K Hold
100
– – ﹤0.01% 864
2022
Q2 		$2.64K Hold
100
– – ﹤0.01% 872
2022
Q1 		$3.5K Hold
100
– – ﹤0.01% 876
2021
Q4 		$3.24K Hold
100
– – ﹤0.01% 909
2021
Q3 		$2.95K Hold
100
– – ﹤0.01% 827
2021
Q2 		$2.56K Hold
100
– – ﹤0.01% 861
2021
Q1 		$1.37K Buy
+100
New +$1.46K ﹤0.01% 904

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Anchor Investment Management's CERE Position: Q3 2024 in Review

Anchor Investment Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 100 shares — an estimated $4.09K sold.

Anchor Investment Management first reported a position in CERE in Q1 2021 and held it in 14 quarters. The position peaked at $4.24K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Anchor Investment Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Anchor Investment Management sold 100 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $4.09K.
  • Anchor Investment Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
  • Anchor Investment Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.24K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Anchor Investment Management's 13F filing for Q3 2024, filed 21 Nov 2024.